Novel MRI assessment of treatment response in HIV-associated NAFLD: a randomized trial of an SCD1 inhibitor (ARRIVE Trial)

Aramchol, an oral stearoyl-coenzyme-A-desaturase-1 (SCD1) inhibitor, has been shown to reduce hepatic-fat content in patients with primary nonalcoholic-fatty-liver-disease (NAFLD), however, its effect in patients with HIV-associated NAFLD is unknown. The ARRIVE trial was a double-blind, randomized,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Hepatology
Egile Nagusiak: Ajmera, Veeral H., Cachay, Edward, Ramers, Christian, Vodkin, Irine, Bassirian, Shirin, Singh, Seema, Mangla, Neeraj, Bettencourt, Richele, Aldous, Jeannette L, Park, Daniel, Lee, Daniel, Blanchard, Jennifer, Mamidipalli, Adrija, Boehringer, Andrew, Aslam, Saima, Leinhard, Olof Dahlqvist, Richards, Lisa, Sirlin, Claude, Loomba, Rohit
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7164416/
https://ncbi.nlm.nih.gov/pubmed/31013363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.30674
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak